A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer - A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer

The University of Tokushima Graduate School0 个研究点目标入组 35 人开始时间: 2010年12月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with the past history of severe allergic reactions 2)Patients with the past history of treatment of irinotecan and panitumumab 3) Patient with active double cancer 4)Patient with active infection 5) Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 6)Patients with severe interstitial pneumonitis or pulmonary fibrosis 7)Patients with uncontrollable ascites and pleural effusion 8)Patients with diarrhea 9) Patient with regular use of furucytocin or fenytoin 10)Patients with symptomatic brain metastasis 11) pregnant or nursing patient or with intent to bear baby 12) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial

发起方

The University of Tokushima Graduate School